Devonian Health Group Inc (GSD) - Total Liabilities

Latest as of April 2026: CA$1.65 Million CAD ≈ $1.19 Million USD

Based on the latest financial reports, Devonian Health Group Inc (GSD) has total liabilities worth CA$1.65 Million CAD (≈ $1.19 Million USD) as of April 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Devonian Health Group Inc to evaluate the company's liquid asset resilience ratio.

Devonian Health Group Inc - Total Liabilities Trend (2015–2025)

This chart illustrates how Devonian Health Group Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Devonian Health Group Inc.

Devonian Health Group Inc Competitors by Total Liabilities

The table below lists competitors of Devonian Health Group Inc ranked by their total liabilities.

Company Country Total Liabilities
BlackRock Virginia MBT
NYSE:BHV
USA $11.78 Million
Toppoint Holdings Inc.
NYSE MKT:TOPP
USA $2.37 Million
Intrasoft Technologies Limited
NSE:ISFT
India Rs568.36 Million
Citigold Corporation Limited
F:CHP
Germany €17.07 Million
Zodiac Energy Limited
NSE:ZODIAC
India Rs-965.64 Million
PYRAMID AG NA O.N.
XETRA:M3B
Germany €32.68 Million
LabGenomics Co. Ltd
KQ:084650
Korea ₩76.00 Billion

Liability Composition Analysis (2015–2025)

This chart breaks down Devonian Health Group Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Devonian Health Group Inc (GSD) balance sheet quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.00 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.24 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.19 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Devonian Health Group Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Devonian Health Group Inc (2015–2025)

The table below shows the annual total liabilities of Devonian Health Group Inc from 2015 to 2025.

Year Total Liabilities Change
2025-07-31 CA$6.69 Million
≈ $4.84 Million
-60.34%
2024-07-31 CA$16.87 Million
≈ $12.21 Million
+242.26%
2023-07-31 CA$4.93 Million
≈ $3.57 Million
-7.22%
2022-07-31 CA$5.31 Million
≈ $3.84 Million
-25.00%
2021-07-31 CA$7.08 Million
≈ $5.12 Million
-3.11%
2020-07-31 CA$7.31 Million
≈ $5.29 Million
+3.41%
2019-07-31 CA$7.07 Million
≈ $5.12 Million
+10.10%
2018-07-31 CA$6.42 Million
≈ $4.65 Million
+90.57%
2017-07-31 CA$3.37 Million
≈ $2.44 Million
-43.33%
2016-07-31 CA$5.95 Million
≈ $4.30 Million
+16718.26%
2016-06-30 CA$35.36K
≈ $25.58K
-99.46%
2015-07-31 CA$6.55 Million
≈ $4.73 Million
--

About Devonian Health Group Inc

V:GSD Canada Biotechnology
Market Cap
$18.00 Million
CA$24.89 Million CAD
Market Cap Rank
#25529 Global
#1006 in Canada
Share Price
CA$8.95
Change (1 day)
+3.77%
52-Week Range
CA$0.14 - CA$14.00
All Time High
CA$14.00
About

Devonian Health Group Inc. operates as a clinical stage biopharmaceutical corporation with novel therapeutic approaches targeting unmet medical needs in Canada and Internationally. It engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for At… Read more